| Year |
Citation |
Score |
| 2023 |
Turner DC, Wada R, Zhou H, Wang X, de Greef R, Valiathan C, Zhang L, Zhang N, Kuchimanchi M, Chen TT, Ballas M, Visser SAG. Model-based meta-analysis of non-small cell lung cancer with standard-of-care PD-1 inhibitors and chemotherapy for early development decision making. Cpt: Pharmacometrics & Systems Pharmacology. PMID 36642813 DOI: 10.1002/psp4.12917 |
0.306 |
|
| 2018 |
Chen T. Designing Late-Stage Randomized Clinical Trials with Cancer Immunotherapy: Can We Make It Simpler? Cancer Immunology Research. 6: 250-254. PMID 31343973 DOI: 10.1158/2326-6066.Cir-17-0465 |
0.411 |
|
| 2017 |
Korn EL, Othus M, Chen T, Freidlin B. Assessing treatment efficacy in the subset of responders in a randomized clinical trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28444115 DOI: 10.1093/Annonc/Mdx197 |
0.344 |
|
| 2016 |
Lineberry N, Berlin JA, Mansi B, Glasser S, Berkwits M, Klem C, Bhattacharya A, Citrome L, Enck R, Fletcher J, Haller D, Chen TT, Laine C. Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. Bmj (Clinical Research Ed.). 355: i5078. PMID 27697753 DOI: 10.1136/Bmj.I5078 |
0.327 |
|
| 2016 |
Chen TT. Predicting analysis times in randomized clinical trials with cancer immunotherapy Data analysis, statistics and modelling Bmc Medical Research Methodology. 16. DOI: 10.1186/S12874-016-0117-3 |
0.39 |
|
| 2015 |
Mick R, Chen TT. Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies. Cancer Immunology Research. 3: 1292-8. PMID 26644449 DOI: 10.1158/2326-6066.Cir-15-0260 |
0.408 |
|
| 2015 |
Chen TT. Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors. Journal of the National Cancer Institute. 107. PMID 26113579 DOI: 10.1093/Jnci/Djv156 |
0.394 |
|
| 2015 |
Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1191-6. PMID 25713437 DOI: 10.1200/Jco.2014.56.6018 |
0.3 |
|
| 2015 |
Chen T. Milestone survival (MS): An alternative survival endpoint in cancer immunotherapies. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E20004 |
0.359 |
|
| 2014 |
Feng Y, Berman D, Chen T, Masson E, Roy A. 1100PIPILIMUMAB (IPI) EXPOSURE-RESPONSE (E-R) AND META-ANALYSIS OF OVERALL SURVIVAL (OS) OF ADVANCED MELANOMA PATIENTS (PTS). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv381. PMID 28171185 DOI: 10.1093/Annonc/Mdu344.16 |
0.355 |
|
| 2014 |
Suciu S, Eggermont AM, Lorigan P, Kirkwood J, Markovic S, Garbe C, Cameron D, Kotapati S, Konto C, Chen T, Wheatley K, Ives N, De Schaetzen G, Efendi A, Buyse M. 1089PDRELAPSE-FREE SURVIVAL (RFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN ADJUVANT INTERFERON TRIALS IN PATIENTS (PTS) WITH RESECTABLE CUTANEOUS MELANOMA: AN INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv376. PMID 28171156 DOI: 10.1093/Annonc/Mdu344.5 |
0.371 |
|
| 2013 |
Chen TT. Statistical issues and challenges in immuno-oncology. Journal For Immunotherapy of Cancer. 1: 18. PMID 24829754 DOI: 10.1186/2051-1426-1-18 |
0.376 |
|
| 2013 |
Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3977-86. PMID 23741070 DOI: 10.1158/1078-0432.Ccr-12-3243 |
0.393 |
|
| 2012 |
Baurain J, Smylie M, Ascierto PA, Roman L, Houston S, Konto C, Chin KM, Chen T, Francis S, Wolchok JD. Outcomes of ipilimumab treatment-related adverse events in patients with metastatic melanoma (MM) who received systemic corticosteroids in a phase III trial. Journal of Clinical Oncology. 30: 8539-8539. DOI: 10.1200/Jco.2012.30.15_Suppl.8539 |
0.369 |
|
| 2011 |
Ibrahim RA, Berman DM, DePril V, Humphrey RW, Chen T, Messina M, Chin KM, Liu HY, Bielefield M, Hoos A. Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8583. PMID 28020999 DOI: 10.1200/Jco.2011.29.15_Suppl.8583 |
0.379 |
|
| Show low-probability matches. |